SCHEMBL468092

SCHEMBL468092

Nc1[c]ccc(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3465 0.72
SCHEMBL644833 0.72
SCHEMBL27458087 0.70
Hydrochloric Acid SCHEMBL9847456 0.70 CYP3A4 (0.36)
Hydrochloric Acid SCHEMBL22092309 0.70
SCHEMBL27436100 0.70
SCHEMBL27680412 0.70
Hydrochloric Acid SCHEMBL4625306 0.70
SCHEMBL9128405 0.69 TAAR1 (0.47)
SCHEMBL4852287 0.69 TSHR (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 822 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117327077-A Anilinopyrimidino heterocyclic compound, and preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-01-02 CN claimed
CN-116947863-A (4-phenoxyphenyl) (pyrrolopyrimidine-5-yl) ketone compound and preparation method and application thereof 中国药科大学 2023-10-27 CN claimed
CN-114874281-A Oleanolic acid derivative and preparation method and application thereof 贵州医科大学 2022-08-09 CN claimed
US-20190071416-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-03-07 US claimed
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 EP claimed
CN-108419435-A Compound and epigenetics for treating cancer 新加坡科技研究局 2018-08-17 CN claimed
EP-2803663-B1 Human protein tyrosine phosphatase inhibitors and their pharmaceutical use AERPIO THERAPEUTICS INC (US) 2017-11-29 EP claimed
WO-2017061957-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-04-13 WO claimed
EP-2803663-A1 Human protein tyrosine phosphatase inhibitors and their pharmaceutical use Aerpio Therapeutics Inc. (US) 2014-11-19 EP claimed
JP-4716984-B2 2011-07-06 JP claimed
WO-2005032490-A2 CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 WO claimed
WO-2005032468-A2 MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 WO claimed
EP-1505966-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 EP claimed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
US-20040204454-A1 Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US claimed
WO-2004082687-A1 LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO claimed
EP-1289950-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2004-09-08 EP claimed
EP-1289972-B1 SERINE PROTEASE INHIBITORS LILLY CO ELI (US) 2004-09-08 EP claimed
CN-1474812-A (dihydro) isoquinoline derivatives as phosphodiesterase inhibitors �ȿˡ��Ŷ��١���ķ������ѧ��˾ 2004-02-11 CN claimed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO claimed